News & Views

Polycystic kidney disease: Tolvaptan slows disease progression in late-stage ADPKD

New data from the REPRISE trial confirms that tolvaptan slows the progression of autosomal dominant polycystic disease (ADPKD). Although not yet approved by the United States Food and Drug administration, tolvaptan is now likely to become standard care for early and later stages of ADPKD in Europe and in various countries worldwide.

  • Subscribe to Nature Reviews Nephrology for full access:

    $199

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    , , , & ERA-EDTA Working Group for Inherited Kidney Diseases. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet 385, 1993–2002 (2015).

  2. 2.

    et al. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int. 86, 1244–1252 (2014).

  3. 3.

    et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N. Engl. J. Med. 377, 1930–1942 (2017).

  4. 4.

    et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407–2418 (2012).

  5. 5.

    , & Autosomal dominant polycystic kidney disease: recent advances in clinical management. F1000Res 5, 2029 (2016).

  6. 6.

    et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol. Dial. Transplant. (2017).

  7. 7.

    et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol. Dial. Transplant. 31, 337–348 (2016).

  8. 8.

    et al. Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 Trial. J. Am. Soc. Nephrol. 28, 1592–1602 (2017).

  9. 9.

    et al. Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 Trial. Clin. J. Am. Soc. Nephrol. 11, 803–811 (2016).

  10. 10.

    & The importance of total kidney volume in evaluating progression of polycystic kidney disease. Nat. Rev. Nephrol. 12, 667–677 (2016).

Download references

Author information

Affiliations

  1. Academic Nephrology Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK.

    • Albert C. M. Ong

Authors

  1. Search for Albert C. M. Ong in:

Competing interests

A.C.M.O. was a site investigator in the TEMPO and REPRISE studies and has received research funding from Otsuka Pharmaceuticals.

Corresponding author

Correspondence to Albert C. M. Ong.